Volume 187, Issue 6 pp. 840-841

Commentary

Immune checkpoint inhibitor-induced cutaneous toxicities: they are not just random

Hanjae Lee,

Hanjae Lee

orcid.org/0000-0002-4455-8001

Department of Dermatology, Seoul National University College of Medicine, Seoul, Republic of Korea

Genomic Medicine Institute (GMI), Medical Research Center, Seoul National University, Seoul, Republic of Korea

Contribution: Conceptualization (equal), Writing - original draft (equal), Writing - review & editing (equal)

Search for more papers by this author

Ohsang Kwon,

Corresponding Author

Ohsang Kwon

[email protected]

orcid.org/0000-0003-0464-5124

Department of Dermatology, Seoul National University College of Medicine, Seoul, Republic of Korea

Genomic Medicine Institute (GMI), Medical Research Center, Seoul National University, Seoul, Republic of Korea

Laboratory of Cutaneous Aging and Hair Research, Clinical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea

Institute of Human Environment Interface Biology, Seoul National University College of Medicine, Seoul, Republic of Korea

Correspondence: Ohsang Kwon.

Email: [email protected]

Contribution: Conceptualization (equal), Writing - original draft (equal), Writing - review & editing (equal)

Search for more papers by this author

Hanjae Lee,

Hanjae Lee

orcid.org/0000-0002-4455-8001

Department of Dermatology, Seoul National University College of Medicine, Seoul, Republic of Korea

Genomic Medicine Institute (GMI), Medical Research Center, Seoul National University, Seoul, Republic of Korea

Contribution: Conceptualization (equal), Writing - original draft (equal), Writing - review & editing (equal)

Search for more papers by this author

Ohsang Kwon,

Corresponding Author

Ohsang Kwon

[email protected]

orcid.org/0000-0003-0464-5124

Department of Dermatology, Seoul National University College of Medicine, Seoul, Republic of Korea

Genomic Medicine Institute (GMI), Medical Research Center, Seoul National University, Seoul, Republic of Korea

Laboratory of Cutaneous Aging and Hair Research, Clinical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea

Institute of Human Environment Interface Biology, Seoul National University College of Medicine, Seoul, Republic of Korea

Correspondence: Ohsang Kwon.

Email: [email protected]

Contribution: Conceptualization (equal), Writing - original draft (equal), Writing - review & editing (equal)

Search for more papers by this author

First published: 02 September 2022

https://doi.org/10.1111/bjd.21838

Conflicts of interest: the authors declare they have no conflicts of interest.

Data availability statement: data sharing not applicable – no new data generated.

Share a link

Email
Wechat
Bluesky

Abstract

Linked Article: Nikolaou et al. Br J Dermatol 2022; 187:962–969.

References

1Wang LL, Patel G, Chiesa-Fuxench ZC et al. Timing of onset of adverse cutaneous reactions associated with programmed cell death protein 1 inhibitor therapy. JAMA Dermatol 2018; 154: 1057–61.
10.1001/jamadermatol.2018.1912
PubMed Web of Science® Google Scholar
2Sibaud V. Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am J Clin Dermatol 2018; 19: 345–61.
10.1007/s40257-017-0336-3
PubMed Web of Science® Google Scholar
3Nikolaou V, Apalla Z, Carrera C et al. Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentric study from the EADV-Task Force of Dermatology for Cancer Patients. Br J Dermatol 2022; 187: 962–9.
10.1111/bjd.21781
CAS PubMed Web of Science® Google Scholar
4Kwon CW, Land AS, Smoller BR et al. Bullous pemphigoid associated with nivolumab, a programmed cell death 1 protein inhibitor. J Eur Acad Dermatol Venereol 2017; 31: e349–50.
10.1111/jdv.14143
CAS PubMed Web of Science® Google Scholar
5Apalla Z, Papageorgiou C, Lallas A et al. Cutaneous adverse events of immune checkpoint inhibitors: a literature review. Dermatol Pract Concept 2021; 11:e2021155.
10.5826/dpc.1101a155
PubMed Google Scholar
6Damsky W, Kole L, Tomayko MM. Development of bullous pemphigoid during nivolumab therapy. JAAD Case Rep 2016; 2: 442–4.
10.1016/j.jdcr.2016.05.009
PubMed Google Scholar
7Lee H, Chung JH, Jo SJ. Pruritic bullous skin eruption in a male patient receiving immunotherapy for oropharyngeal cancer. Int J Dermatol 2020; 59: 685–6.
10.1111/ijd.14742
PubMed Web of Science® Google Scholar

Volume187, Issue6

December 2022

Pages 840-841

Immune checkpoint inhibitor-induced cutaneous toxicities: they are not just random

Abstract

References

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Immune checkpoint inhibitor-induced cutaneous toxicities: they are not just random

Abstract

References

References

Related

Information